These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Kaufman DW; Kelly JP; Anderson T; Harmon DC; Shapiro S Epilepsia; 1997 Dec; 38(12):1265-9. PubMed ID: 9578520 [TBL] [Abstract][Full Text] [Related]
8. From the Food and Drug Administration. Nightingale SL JAMA; 1994 Oct; 272(13):995. PubMed ID: 8089899 [No Abstract] [Full Text] [Related]
9. Evaluating the safety and efficacy of felbamate in the context of a black box warning: A single center experience. Shah YD; Singh K; Friedman D; Devinsky O; Kothare SV Epilepsy Behav; 2016 Mar; 56():50-3. PubMed ID: 26828692 [TBL] [Abstract][Full Text] [Related]
11. The rise and fall of felbamate as a treatment for partial epilepsy--aplastic anemia and hepatic failure to blame? Thakkar K; Billa G; Rane J; Chudasama H; Goswami S; Shah R Expert Rev Neurother; 2015; 15(12):1373-5. PubMed ID: 26566191 [TBL] [Abstract][Full Text] [Related]
12. FDA recommends taking patients off Felbatol. RDH; 1994 Sep; 14(9):36. PubMed ID: 8619071 [No Abstract] [Full Text] [Related]
13. Is there any future for felbamate treatment? Borowicz KK; Piskorska B; Kimber-Trojnar Z; Małek R; Sobieszek G; Czuczwar SJ Pol J Pharmacol; 2004; 56(3):289-94. PubMed ID: 15215558 [TBL] [Abstract][Full Text] [Related]
15. Investigating the role of 2-phenylpropenal in felbamate-induced idiosyncratic drug reactions. Popović M; Nierkens S; Pieters R; Uetrecht J Chem Res Toxicol; 2004 Dec; 17(12):1568-76. PubMed ID: 15606131 [TBL] [Abstract][Full Text] [Related]